QIAGEN Enters Into Broad Collaboration Agreement With Lilly for the Development and Commercialization of Companion Diagnostics

Wed Feb 13, 2013 4:00pm EST

* Reuters is not responsible for the content in this press release.

For best results when printing this announcement, please click on the link


GERMANTOWN, Maryland  and HILDEN,  Germany,  February 13, 2013  /PRNewswire/ --

* Arrangement to facilitate future collaborations in personalized medicine
* Provides framework to develop and commercialize QIAGEN companion diagnostics
paired with Lilly medicines in an effort to improve outcomes for individual
* Builds on the two companies' recent mutual successes

QIAGEN (NASDAQ: QGEN;  Frankfurt, Prime Standard: QIA) today announced it has
entered into a master collaboration agreement with Eli Lilly and Company (NYSE:
LLY) for the development and commercialization of companion diagnostics for
pairing with Lilly investigational and approved medicines across all therapeutic
areas. The agreement builds on QIAGEN and Lilly's past work together. Companion
diagnostics unlock a patient's molecular information in order to guide treatment
decisions for specific cancers or other diseases. Financial terms of the
agreement are not being disclosed.

The agreement provides a framework for Lilly and QIAGEN to collaborate on future
projects - across all of Lilly's therapeutic areas - aimed at bringing to market
Lilly medicines paired with QIAGEN diagnostics. It also further underscores
QIAGEN's leading position in partnering with global pharmaceutical companies to
deliver the benefits of personalized medicine to patients and healthcare

"Tailored therapies are a key component of Lilly's strategy of providing
improved outcomes for individual patients. By working with partners like QIAGEN,
we are advancing a number of tailored therapeutics in an effort to target the
right medicine to the right patient," said  Daniel Skovronsky, M.D., Ph.D., vice
president, tailored therapeutics, Lilly, and chief executive officer, Avid
Radiopharmaceuticals, a wholly-owned subsidiary of Lilly. "This collaboration
with QIAGEN extends our capabilities to more quickly and cost-effectively bring
innovative new medicines, alongside advanced diagnostics, to patients worldwide
who are waiting."

"We have expanded this relationship with Lilly as a result of our ongoing work
together," said Dr.  Ulrich Schriek, Senior Vice President Global Business
Development of QIAGEN. "This agreement lays the groundwork for potential future
projects with Lilly in various therapeutic areas and enables significant
efficiencies for future development programs by standardizing interfaces and
processes between our organizations. Through partnerships like this, QIAGEN
offers pharma companies a cost-effective way to maximize the value and benefits
of potential new medicines in their pipelines, while also reducing the risks in
medicine development."

QIAGEN is at the forefront globally in developing and validating Personalized
Healthcare tests that provide physicians with genomic information on each
patient to guide the selection of medicines in treating cancer and other
diseases. QIAGEN is actively expanding its pipeline of tests for important
biomarkers and intends to submit several companion diagnostics for U.S.
regulatory approval. Last month, QIAGEN announced submission of its 
therascreen®  EGFR RGQ PCR Kit test to the FDA as a proposed companion
diagnostic to guide treatment with a new investigational oncology compound
developed by Boehringer Ingelheim. QIAGEN is engaged in more than 15 projects
with leading pharmaceutical and biotech companies to co-develop and market
companion diagnostics.

QIAGEN and Lilly have previously collaborated on companion diagnostics designed
to run on QIAGEN's Rotor-Gene Q system, a component of the QIAsymphony family of
automated instruments, which is revolutionizing laboratory workflows. QIAGEN's
strategy is to develop FDA-approved diagnostics in  the United States  for use
on this platform.

Photos on Personalized Healthcare are available online for free download at: 


QIAGEN N.V., a  Netherlands  holding company, is the leading global provider of
Sample & Assay Technologies that are used to transform biological materials into
valuable molecular information. Sample technologies are used to isolate and
process  DNA,  RNA  and proteins from biological samples such as blood or
tissue. Assay technologies are then used to make these isolated biomolecules
visible and ready for interpretation. QIAGEN markets more than 500 products
around the world, selling both consumable kits and automation systems to
customers through four customer classes:  Molecular Diagnostics  (human
healthcare),  Applied Testing  (forensics, veterinary testing and food safety),
Pharma (pharmaceutical and biotechnology companies) and Academia (life sciences
research). As of  December 31, 2012, QIAGEN employed approximately 4,000 people
in more than 35 locations worldwide. Further information can be found at 

Certain of the statements contained in this news release may be considered
forward-looking statements within the meaning of Section 27A of the U.S.
Securities Act of 1933, as amended, and Section 21E of the U.S. Securities
Exchange Act of 1934, as amended. To the extent that any of the statements
contained herein relating to QIAGEN's products, markets, strategy or operating
results, including without limitation its expected operating results, are
forward-looking, such statements are based on current expectations and
assumptions that involve a number of uncertainties and risks. Such uncertainties
and risks include, but are not limited to, risks associated with management of
growth and international operations (including the effects of currency
fluctuations, regulatory processes and dependence on logistics), variability of
operating results and allocations between customer classes, the commercial
development of markets for our products inapplied testing, personalized
healthcare, clinical research,proteomics, women's health/HPVtesting andnucleic
acid-basedmolecular diagnostics; changing relationships with customers,
suppliers and strategic partners; competition; rapid or unexpected changes in
technologies; fluctuations in demand for QIAGEN's products (including
fluctuations due to general economic conditions, the level and timing of
customers' funding, budgets and other factors); our ability to obtain regulatory
approval of our products; difficulties in successfully adapting QIAGEN's
products to integrated solutions and producing such products; the ability of
QIAGEN to identify and develop new products and to differentiate and protect our
products from competitors' products; market acceptance of QIAGEN's new products,
the consummation of acquisitions, and the integration of acquired technologies
and businesses. For further information, please refer to the discussions in
reports that QIAGEN has filed with, or furnished to, the U.S. Securities and
Exchange Commission (SEC).

Public Relations:

Dr.  Thomas Theuringer

Director Public Relations



Email:  pr@qiagen.com


Investor Relations:
John Gilardi

VP Corporate Communications



Peter Vozzo

Director, Global Investor Relations


Email:  ir@qiagen.com


SOURCE  Qiagen N.V.

Comments (0)
This discussion is now closed. We welcome comments on our articles for a limited period after their publication.